Symbols / INM $0.86 +0.34%
INM Chart
About
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with unmet medical needs. The company's lead product consists of INM-755, a cannabinol topical skin cream that has completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, a small molecule compound that acts as a selective dual CB1/CB2 agonist; and INM-900 for neurodegenerative diseases, as well as INM-901, a small molecule for treatment of Alzheimer's disease. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 2.52M |
| Enterprise Value | -3.95M | Income | -7.66M | Sales | 4.51M |
| Book/sh | 3.42 | Cash/sh | 2.40 | Dividend Yield | — |
| Payout | 0.00% | Employees | 13 | IPO | — |
| P/E | — | Forward P/E | -0.14 | PEG | — |
| P/S | 0.56 | P/B | 0.25 | P/C | — |
| EV/EBITDA | 0.52 | EV/Sales | -0.88 | Quick Ratio | 4.85 |
| Current Ratio | 5.94 | Debt/Eq | 5.55 | LT Debt/Eq | — |
| EPS (ttm) | -2.88 | EPS next Y | -6.25 | EPS Growth | — |
| Revenue Growth | -26.20% | Earnings | 2026-05-12 | ROA | -49.77% |
| ROE | -97.20% | ROIC | — | Gross Margin | 29.73% |
| Oper. Margin | -258.57% | Profit Margin | -170.07% | Shs Outstand | 2.92M |
| Shs Float | 2.09M | Short Float | 3.16% | Short Ratio | 1.94 |
| Short Interest | — | 52W High | 7.98 | 52W Low | 0.73 |
| Beta | 0.46 | Avg Volume | 89.96K | Volume | 4.99K |
| Target Price | — | Recom | None | Prev Close | $0.86 |
| Price | $0.86 | Change | 0.34% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.90
Latest analyst target
3. DCF / Fair value
$-26.55
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.90
Low
—
High
—
Mean
—
News
RSS: Latest INM news- U.S. law threat pushes InMed to shut BayMedica unit, pivot to Alzheimer's drugs - Stock Titan Fri, 06 Mar 2026 08
- InMed's 2026 push to bring Alzheimer's, eye drug candidates to human testing - Stock Titan Mon, 09 Mar 2026 11
- Can InMed Pharmaceuticals Stock Recover If Markets Fall? - Trefis Sun, 14 Dec 2025 08
- InMed outlines 2026 development plans for lead programs - TipRanks Mon, 09 Mar 2026 12
- 12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga Wed, 04 Mar 2026 08
- Anthropic’s COBOL tool triggers worst single-day drop in 25 years in IBM's stock price: What it is and wh - The Times of India ue, 24 Feb 2026 08
- How to buy Google stock: Investing in GOOGL (Alphabet) - NerdWallet Fri, 09 Jan 2026 08
- Top 5 Small-cap Pharma Stocks (Updated January 2026) - Investing News Network Mon, 05 Jan 2026 08
- INM Pharma Stock’s Sudden Leap: What’s Next? - StocksToTrade Mon, 02 Jun 2025 07
- InMed Pharmaceuticals Experiences Market Shifts Amidst Unstable Global Economy - timothysykes.com ue, 18 Nov 2025 08
- The 10 Biggest Tech Companies in the World | Investing - US News Money ue, 14 Oct 2025 07
- InMed Pharmaceuticals reports FY25 EPS ($8.36) vs ($20.14) last year - Yahoo Finance Wed, 24 Sep 2025 07
- symbol__ Stock Quote Price and Forecast - CNN Wed, 27 Mar 2024 06
- A Salesforce board member bought $1 million in stock near recent lows. He has a good track record. - MarketWatch Mon, 07 Apr 2025 07
- 12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga Mon, 09 Mar 2026 21
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 240 | 42 | — | Sale at price 0.18 per share. | MANCINI ALEXANDRA DIANE JANET | Unknown | — | 2024-07-31 00:00:00 | D |
Financials
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | -9.29K | -19.27K | 0.00 |
| TaxRateForCalcs | 0.00 | 0.15 | 0.40 | 0.00 |
| NormalizedEBITDA | -7.23M | -7.00M | -7.73M | -8.38M |
| TotalUnusualItems | -28.47K | -61.92K | -48.17K | -4.90M |
| TotalUnusualItemsExcludingGoodwill | -28.47K | -61.92K | -48.17K | -4.90M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -8.16M | -7.68M | -7.95M | -18.60M |
| ReconciledDepreciation | 534.73K | 604.52K | 596.00K | 511.79K |
| ReconciledCostOfRevenue | 2.91M | 3.11M | 2.34M | 219.76K |
| EBITDA | -7.26M | -7.06M | -7.78M | -13.28M |
| EBIT | -7.79M | -7.67M | -8.38M | -13.79M |
| NetInterestIncome | -215.67K | 527.90K | 492.44K | 96.09K |
| InterestExpense | 371.55K | 0.00 | 0.00 | 360.35K |
| InterestIncome | 155.88K | 527.90K | 492.44K | 96.09K |
| NormalizedIncome | -8.13M | -7.62M | -7.92M | -13.70M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -8.16M | -7.68M | -7.95M | -18.60M |
| TotalExpenses | 12.86M | 12.73M | 12.51M | 14.88M |
| DilutedAverageShares | 975.99K | 381.05K | 122.42K | 28.04K |
| BasicAverageShares | 975.99K | 381.05K | 122.42K | 28.04K |
| DilutedEPS | -8.36 | -20.20 | -65.00 | -663.40 |
| BasicEPS | -8.36 | -20.20 | -65.00 | -663.40 |
| DilutedNIAvailtoComStockholders | -8.16M | -7.68M | -7.95M | -18.60M |
| NetIncomeCommonStockholders | -8.16M | -7.68M | -7.95M | -18.60M |
| NetIncome | -8.16M | -7.68M | -7.95M | -18.60M |
| NetIncomeIncludingNoncontrollingInterests | -8.16M | -7.68M | -7.95M | -18.60M |
| NetIncomeContinuousOperations | -8.16M | -7.68M | -7.95M | -18.60M |
| TaxProvision | 0.00 | 7.10K | 13.10K | 0.00 |
| PretaxIncome | -8.16M | -7.67M | -7.93M | -18.60M |
| OtherIncomeExpense | -28.47K | -61.92K | -48.17K | -4.90M |
| SpecialIncomeCharges | 0.00 | -3.47M | 0.00 | |
| ImpairmentOfCapitalAssets | 0.00 | 3.47M | 0.00 | |
| GainOnSaleOfSecurity | -28.47K | -61.92K | -48.17K | -1.43M |
| NetNonOperatingInterestIncomeExpense | -215.67K | 527.90K | 492.44K | 96.09K |
| InterestExpenseNonOperating | 371.55K | 0.00 | 0.00 | 360.35K |
| InterestIncomeNonOperating | 155.88K | 527.90K | 492.44K | 96.09K |
| OperatingIncome | -7.92M | -8.13M | -8.38M | -13.79M |
| OperatingExpense | 9.62M | 9.24M | 9.78M | 14.34M |
| DepreciationAmortizationDepletionIncomeStatement | 212.84K | 219.60K | 202.25K | 185.66K |
| DepreciationAndAmortizationInIncomeStatement | 212.84K | 219.60K | 202.25K | 185.66K |
| ResearchAndDevelopment | 2.85M | 3.22M | 3.73M | 7.28M |
| SellingGeneralAndAdministration | 6.56M | 5.80M | 5.85M | 6.87M |
| GeneralAndAdministrativeExpense | 6.56M | 5.80M | 5.85M | 6.87M |
| OtherGandA | 6.56M | 5.80M | 5.85M | 6.87M |
| GrossProfit | 1.71M | 1.10M | 1.40M | 543.55K |
| CostOfRevenue | 3.24M | 3.50M | 2.73M | 545.89K |
| TotalRevenue | 4.94M | 4.60M | 4.14M | 1.09M |
| OperatingRevenue | 4.94M | 4.60M | 4.14M | 1.09M |
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| OrdinarySharesNumber | 2.00M | 445.95K | 166.41K | 32.53K |
| ShareIssued | 2.00M | 445.95K | 166.41K | 32.53K |
| TotalDebt | 741.26K | 962.66K | 391.71K | 793.77K |
| TangibleBookValue | 11.81M | 7.42M | 10.14M | 6.97M |
| InvestedCapital | 13.43M | 9.21M | 12.09M | 9.08M |
| WorkingCapital | 11.03M | 6.72M | 9.33M | 6.28M |
| NetTangibleAssets | 11.81M | 7.42M | 10.14M | 6.97M |
| CapitalLeaseObligations | 741.26K | 962.66K | 391.71K | 793.77K |
| CommonStockEquity | 13.43M | 9.21M | 12.09M | 9.08M |
| TotalCapitalization | 13.43M | 9.21M | 12.09M | 9.08M |
| TotalEquityGrossMinorityInterest | 13.43M | 9.21M | 12.09M | 9.08M |
| StockholdersEquity | 13.43M | 9.21M | 12.09M | 9.08M |
| GainsLossesNotAffectingRetainedEarnings | 128.57K | 128.57K | 128.57K | 128.57K |
| OtherEquityAdjustments | 128.57K | 128.57K | 128.57K | 128.57K |
| ForeignCurrencyTranslationAdjustments | 128.57K | 128.57K | ||
| RetainedEarnings | -117.24M | -109.08M | -101.40M | -93.45M |
| AdditionalPaidInCapital | 39.32M | 35.37M | 35.74M | 31.68M |
| CapitalStock | 91.22M | 82.78M | 77.62M | 70.72M |
| CommonStock | 91.22M | 82.78M | 77.62M | 70.72M |
| TotalLiabilitiesNetMinorityInterest | 2.15M | 2.62M | 2.02M | 3.71M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 305.75K | 644.87K | 15.99K | 389.50K |
| LongTermDebtAndCapitalLeaseObligation | 305.75K | 644.87K | 15.99K | 389.50K |
| LongTermCapitalLeaseObligation | 305.75K | 644.87K | 15.99K | 389.50K |
| CurrentLiabilities | 1.84M | 1.97M | 2.00M | 3.32M |
| CurrentDeferredLiabilities | 0.00 | 16.17K | 0.00 | |
| CurrentDebtAndCapitalLeaseObligation | 435.51K | 317.80K | 375.71K | 404.28K |
| CurrentCapitalLeaseObligation | 435.51K | 317.80K | 375.71K | 404.28K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 490.40K | 488.28K | 542.30K | 139.12K |
| PayablesAndAccruedExpenses | 913.88K | 1.17M | 1.07M | 2.78M |
| CurrentAccruedExpenses | 543.74K | 539.54K | 522.25K | 1.11M |
| Payables | 370.14K | 626.19K | 544.18K | 1.67M |
| OtherPayable | 500.00K | |||
| AccountsPayable | 370.14K | 626.19K | 544.18K | 1.17M |
| TotalAssets | 15.58M | 11.82M | 14.11M | 12.79M |
| TotalNonCurrentAssets | 2.71M | 3.13M | 2.77M | 3.19M |
| OtherNonCurrentAssets | 100.00K | 100.00K | 104.91K | 176.64K |
| GoodwillAndOtherIntangibleAssets | 1.62M | 1.78M | 1.95M | 2.11M |
| OtherIntangibleAssets | 1.62M | 1.78M | 1.95M | 2.11M |
| NetPPE | 992.20K | 1.25M | 723.43K | 904.25K |
| AccumulatedDepreciation | -1.34M | -1.36M | -925.32K | -516.47K |
| GrossPPE | 2.33M | 2.61M | 1.65M | 1.42M |
| Leases | 40.41K | 42.99K | ||
| OtherProperties | 2.33M | 2.56M | 1.61M | 1.38M |
| MachineryFurnitureEquipment | 0.00 | 40.41K | 40.41K | 40.41K |
| Properties | 0.00 | 0.00 | ||
| CurrentAssets | 12.87M | 8.69M | 11.33M | 9.60M |
| OtherCurrentAssets | 321.75K | 477.75K | 498.03K | 797.23K |
| RestrictedCash | 43.38K | 43.06K | 44.42K | 44.80K |
| PrepaidAssets | 797.23K | 956.76K | ||
| Inventory | 961.17K | 1.24M | 1.62M | 2.49M |
| FinishedGoods | 676.18K | 840.81K | 893.51K | 473.43K |
| WorkInProcess | 26.70K | 30.82K | 514.11K | 1.72M |
| RawMaterials | 258.30K | 372.69K | 208.74K | 292.58K |
| Receivables | 465.10K | 352.84K | 260.40K | 88.03K |
| AccountsReceivable | 465.10K | 352.84K | 260.40K | 88.03K |
| AllowanceForDoubtfulAccountsReceivable | -2.42K | 0.00 | -66.78K | |
| GrossAccountsReceivable | 467.53K | 352.84K | 327.17K | |
| CashCashEquivalentsAndShortTermInvestments | 11.08M | 6.57M | 8.91M | 6.18M |
| OtherShortTermInvestments | 44.80K | 46.46K | ||
| CashAndCashEquivalents | 11.08M | 6.57M | 8.91M | 6.18M |
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| FreeCashFlow | -7.77M | -7.00M | -7.45M | -15.62M |
| RepaymentOfDebt | 0.00 | -290.83K | 0.00 | |
| IssuanceOfCapitalStock | 8.13M | 5.22M | 10.68M | 17.15M |
| CapitalExpenditure | -9.29K | -161.80K | -39.11K | -1.73K |
| InterestPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| IncomeTaxPaidSupplementalData | 0.00 | 7.10K | 13.10K | 0.00 |
| EndCashPosition | 11.08M | 6.57M | 8.91M | 6.18M |
| BeginningCashPosition | 6.57M | 8.91M | 6.18M | 7.36M |
| EffectOfExchangeRateChanges | 0.00 | 494.96K | ||
| ChangesInCash | 4.50M | -2.34M | 2.74M | -1.19M |
| FinancingCashFlow | 12.27M | 4.65M | 10.68M | 15.07M |
| CashFlowFromContinuingFinancingActivities | 12.27M | 4.65M | 10.68M | 15.07M |
| NetOtherFinancingCharges | -883.98K | -562.15K | -1.32M | -1.78M |
| ProceedsFromStockOptionExercised | 5.02M | 175.00 | 646.00 | |
| NetCommonStockIssuance | 8.13M | 5.22M | 10.68M | 17.15M |
| CommonStockIssuance | 8.13M | 5.22M | 10.68M | 17.15M |
| NetIssuancePaymentsOfDebt | 0.00 | -290.83K | 0.00 | |
| NetLongTermDebtIssuance | 0.00 | -290.83K | 0.00 | |
| LongTermDebtPayments | 0.00 | -290.83K | 0.00 | |
| InvestingCashFlow | 0.00 | -9.29K | -661.80K | -673.00K |
| CashFlowFromContinuingInvestingActivities | 0.00 | -9.29K | -661.80K | -673.00K |
| NetOtherInvestingChanges | -425.00K | |||
| NetInvestmentPurchaseAndSale | 0.00 | 0.00 | 0.00 | 0.00 |
| SaleOfInvestment | 42.27K | 42.08K | 42.27K | 0.00 |
| PurchaseOfInvestment | -42.27K | -42.08K | -42.27K | 0.00 |
| NetBusinessPurchaseAndSale | 0.00 | -500.00K | -208.89K | 0.00 |
| SaleOfBusiness | 0.00 | 91.57K | 0.00 | |
| PurchaseOfBusiness | 0.00 | -500.00K | -300.46K | 0.00 |
| NetPPEPurchaseAndSale | 0.00 | -9.29K | -161.80K | -39.11K |
| SaleOfPPE | 0.00 | |||
| PurchaseOfPPE | 0.00 | -9.29K | -161.80K | -39.11K |
| OperatingCashFlow | -7.77M | -6.99M | -7.28M | -15.58M |
| CashFlowFromContinuingOperatingActivities | -7.77M | -6.99M | -7.28M | -15.58M |
| InterestReceivedCFO | 131.00 | |||
| ChangeInWorkingCapital | -337.17K | -369.34K | -565.82K | -3.07M |
| ChangeInOtherWorkingCapital | -16.17K | 16.17K | -5.14K | |
| ChangeInOtherCurrentLiabilities | -429.88K | -397.42K | -426.57K | -341.86K |
| ChangeInOtherCurrentAssets | 0.00 | 4.91K | 5.51K | -61.43K |
| ChangeInPayablesAndAccruedExpense | -249.73K | 45.28K | -806.53K | -811.60K |
| ChangeInPrepaidAssets | 173.98K | 20.28K | 299.19K | 190.66K |
| ChangeInInventory | 283.15K | 66.22K | 565.56K | -2.00M |
| ChangeInReceivables | -114.69K | -92.44K | -219.15K | -40.01K |
| ChangesInAccountReceivables | -114.69K | -92.44K | -219.15K | -40.01K |
| OtherNonCashItems | -35.00 | -1.25K | -803.00 | 1.39M |
| StockBasedCompensation | 119.31K | 137.71K | 278.15K | 697.89K |
| ProvisionandWriteOffofAssets | 2.42K | 0.00 | 46.77K | 0.00 |
| AssetImpairmentCharge | 0.00 | 305.81K | 308.94K | 3.47M |
| DepreciationAmortizationDepletion | 534.73K | 604.52K | 596.00K | 511.79K |
| DepreciationAndAmortization | 534.73K | 604.52K | 596.00K | 511.79K |
| AmortizationCashFlow | 162.64K | 171.86K | 202.25K | 159.23K |
| AmortizationOfIntangibles | 162.64K | 171.86K | 202.25K | 159.23K |
| Depreciation | 372.09K | 432.66K | 393.75K | 352.56K |
| OperatingGainsLosses | 75.93K | 12.26K | 1.18K | 13.12K |
| GainLossOnInvestmentSecurities | -242.63K | |||
| NetForeignCurrencyExchangeGainLoss | 75.93K | 12.26K | 1.18K | 1.77K |
| NetIncomeFromContinuingOperations | -8.16M | -7.68M | -7.95M | -18.60M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for INM
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|